Showing posts with label Avila Therapeutics. Show all posts
Showing posts with label Avila Therapeutics. Show all posts

Saturday, January 28, 2012

Celgene buys it's way into a feverish Hepatitis C market...

An article from Investor's Business Daily on recent biotech mergers, including Celgene's recent purchase of Avila Therapeutics, which may also put Celgene in the HCV DAA marketplace. I need a scorecard to keep up!

Gilead, Celgene Join Big Pharma On M&A Front
 By MARILYN ALVA, INVESTOR'S BUSINESS DAILY Posted 01/27/2012 02:19 PM ET

The biotech industry is gripped with acquisition fever.

Celgene (CELG) was the latest to catch the fever, announcing Thursday it would buy privately held Avila Therapeutics for $350 million.

The move expands Celgene's market-leading blood cancer arsenal, which includes top-gun Revlimid, by adding Avila's experimental drug therapy known as AVL-292, now in clinical development.

Gene mapping is making drug development more precise, targeting patients with certain genetic markers.
Avila also brings Celgene into the hot hepatitis C treatment arena with drugs called protease inhibitors now in preclinical development.

Biotech firms are racing to bring new hepatitis C drugs to market to replace the current regimen of virus-fighting cocktails, including injectable interferon, which often has crippling side effects.

The Celgene/Avila deal is small potatoes compared with HIV-focused Gilead Sciences' (GILD) recent acquisition of Pharmasset.

Gilead paid $11.2 billion, a huge premium, to get its hands on the company's hepatitis C drugs still in development.

The deal was unusual not only for its size, but also for the type of outfit doing the buying: another biotech firm.

Biotech mergers and acquisitions are not new. But biotech firms usually make smaller buys.

It's the large diversified drug firms that typically pay big money for biotech firms to offset blockbuster drugs losing patent protection and shrinking development pipelines.

Last year, France's Sanofi-Aventis (SNY) paid $20 billion for the remaining interest it had in Genzyme.

In 2009, Swiss drug giant Roche Holding (RHHBY) bought Genentech, the granddaddy of biotechs, for a cool $46.8 billion, giving it reason to declare itself the biggest biotech company in the world.

"Gilead's $11 billion acquisition really opened eyes for the potential of biotech companies to be big acquirers as well," said Steven Silver, biotech equity analyst with S&P Capital IQ.

Gilead, and now Celgene, are among a host of companies buying their way into new treatments for the hepatitis C virus, which affects liver function and afflicts some 170 million people worldwide.

Big Pharma is also on the hepatitis C warpath. In early January, Bristol-Myers Squibb (BMY) said it would pay $2.5 billion for biotech firm Inhibitex (INHX) to expand its war chest of hepatitis C drugs in development.

Its announcement came after Roche agreed to buy biotech outfit Anadys Pharmaceuticals (ANDS) for $250 million to bolster its hepatitis C pipeline.

"The hot theme for mergers and acquisitions right now is hepatitis C," said Silver.

Wednesday, December 1, 2010

"Sticking Fast To Foil Hepatitis C" article from Chemistry & Engineering News...

A deeper look on Avila Therapeutics development of new protease blockers that irreversibly inhibit the HCV protease enzyme - Chris

Biochemistry: Aiming beyond the active site of a virus's key protease yields selective blockers

Carmen Drahl

By targeting a noncatalytic cysteine, researchers have designed selective irreversible blockers of a protease enzyme essential for hepatitis C virus replication (Nat. Chem. Biol., DOI: 10.1038/nchembio.492).

The work is the first demonstration that steering clear of the active site is a viable design strategy for drugs that react to form a covalent bond to proteases, a broad class of proteins that includes many drug targets. This strategy has already proven useful for blocking other proteins such as kinases.

A team from the biotechnology company Avila Therapeutics developed the new protease blockers, which covalently bind to a cysteine in hepatitis C protease's substrate-binding site. In contrast, most other hepatitis C protease inhibitors in development reversibly bind to a catalytic amino acid common to proteases in human hosts as well as in viruses. Avila's published inhibitor structures are prototypes, but the company hopes to begin human clinical trials with optimized compounds in 2011. The team says its comprehensive structural analysis of hundreds of proteases suggests this strategy can be applied broadly.

However, it's not clear how applicable the team's strategy will be to all proteases, says Matthew S. Bogyo of Stanford University, who develops chemical tools to study the roles of proteases in disease. Nevertheless, "covalent inhibitors benefit from a long duration of action, and when used for clearing pathogens such as hepatitis C virus, they may make more sense than classical reversible inhibitors," Bogyo says. Covalent inhibitors can also make several aspects of drug development more straightforward because it's easier to monitor their target selectivity and distribution throughout the body compared with reversible inhibitors, he adds.

Sunday, November 28, 2010

Avilla Therapeutics publishes paper on a new class of highly selective, irreversible HCV protease inhibitors

Publication in Nature Chemical Biology demonstrates that irreversible covalent inhibition can increase selectivity, potency and duration of action, broadens applications for targeted covalent drugs to the protease gene family

WALTHAM, MA – November 28, 2010 – Avila Therapeutics™, Inc., a biotechnology company developing novel targeted covalent drugs, has published research in Nature Chemical Biology demonstrating the first-ever selective irreversible inhibition of a viral protease using a targeted covalent drug. In the paper titled "Selective Irreversible Inhibition of a Protease by Targeting a Non-Catalytic Cysteine", Avila used its proprietary Avilomics™ platform to design covalent irreversible protease inhibitors that are highly selective, potent and with superior duration of action as compared to conventional protease inhibitors.

Importantly, the published research demonstrates that covalent drugs can be designed and targeted to irreversibly and covalently bond to molecular domains specific to proteases. This is the first report of the irreversible covalent approach being successfully extended to proteases, a very broad class of proteins that includes many important potential drug targets.

"This research elevates covalent drug design to a fundamentally new level," said Simon Campbell, PhD, CBE, FMedSci, FRS, a renowned scientist and former Senior Vice President for Worldwide Drug Discovery and Medicinal R&D Europe of Pfizer. "By creating extremely selective protease inhibitors with their platform, Avila is showing the remarkable therapeutic potential of irreversible covalent drugs to address a broad spectrum of drug targets."

"This publication showcases the creation of a whole new class of small molecule drugs," said Juswinder Singh, PhD, Chief Scientific Officer of Avila and a co-author of the paper. "This approach can make a difference to patients living with HCV infection, and we expect to make an impact in other important areas such as cancer and inflammatory disease."

In order to maximize selectivity and minimize off-target effects, the irreversible covalent inhibitors of HCV protease were designed to covalently target a unique structure in the HCV protease not found in human proteases. Key findings include:

* A representative irreversible covalent inhibitor designed, by Avila, was shown to inhibit the HCV protease (also known as "NS3") in cells at a concentration of 6 nM .
* Specific covalent bond formation between the drug and target protease was demonstrated through use of mass spectrometry and also x-ray crystallography.
* Very high selectivity of the Avila compounds was demonstrated by showing no notable inhibition of a panel of human proteases in biochemical assays with additional specificity demonstrated in cellular assays; this was contrasted experimentally with Telaprevir, an HCV protease inhibitor in late-stage clinical testing which demonstrated off-target biochemical activity against several human targets.

Avila has subsequently optimized additional drug candidates, yielding current development candidates, AVL-181 and AVL-192, which have excellent pharmacokinetics and bind potently to wild- type HCV protease as well as multiple genotypes and mutant forms of HCV protease.

###

About Avila Therapeutics™, Inc.

Avila focuses on design and development of targeted covalent drugs to achieve best-in class outcomes that cannot be achieved through traditional chemistries. This approach is called "protein silencing". The company's product pipeline has been built using its proprietary Avilomics™ platform and is currently focused on viral infection, cancer and autoimmune disease. Avila is funded by leading venture capital firms: Abingworth, Advent Venture Partners, Atlas Venture, Novartis Option Fund, and Polaris Venture Partners. For additional information, please visit http://www.avilatx.com